MAGE A4 (230-239)

MAGE A4 (230-239) is a peptide sequence derived from the MAGE-A4 protein. MAGE A4 (230-239) is an immunogenic epitope that can activate T cells and trigger the killing of tumor cells expressing MAGE-A4. MAGE A4 (230-239) is used in the development of next-generation T cell-based immunotherapies[1].

Product Specifications

CAS Number

[252875-61-9]

UNSPSC

12352209

Target

Others

Type

Peptides

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mage-a4-230-239.html

Smiles

O=C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CC(O)=O)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC2=CNC=N2)C(N[C@@H]([C@H](O)C)C(N[C@@H](C(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CN

Molecular Formula

C48H73N15O17

Molecular Weight

1132.18

References & Citations

[1]Davari K, et al. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy[J]. Journal for Immunotherapy of Cancer, 2021, 9 (3) .